JP6625061B2 - 固形腫瘍癌を検出する方法 - Google Patents

固形腫瘍癌を検出する方法 Download PDF

Info

Publication number
JP6625061B2
JP6625061B2 JP2016556777A JP2016556777A JP6625061B2 JP 6625061 B2 JP6625061 B2 JP 6625061B2 JP 2016556777 A JP2016556777 A JP 2016556777A JP 2016556777 A JP2016556777 A JP 2016556777A JP 6625061 B2 JP6625061 B2 JP 6625061B2
Authority
JP
Japan
Prior art keywords
psa
biomarker
cancer
risk
biological sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016556777A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017508970A (ja
JP2017508970A5 (enExample
Inventor
ヘンリク・グレンバリ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phadia AB
Original Assignee
Phadia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phadia AB filed Critical Phadia AB
Publication of JP2017508970A publication Critical patent/JP2017508970A/ja
Publication of JP2017508970A5 publication Critical patent/JP2017508970A5/ja
Application granted granted Critical
Publication of JP6625061B2 publication Critical patent/JP6625061B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G01N33/575—
    • G01N33/57555—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G01N33/57565—
    • G01N33/5758—
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
JP2016556777A 2014-03-11 2015-03-11 固形腫瘍癌を検出する方法 Expired - Fee Related JP6625061B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1450274 2014-03-11
SE1450274-4 2014-03-11
SE1450420-3 2014-04-04
SE1450420 2014-04-04
PCT/SE2015/050272 WO2015137870A1 (en) 2014-03-11 2015-03-11 Method for detecting a solid tumor cancer

Publications (3)

Publication Number Publication Date
JP2017508970A JP2017508970A (ja) 2017-03-30
JP2017508970A5 JP2017508970A5 (enExample) 2018-04-19
JP6625061B2 true JP6625061B2 (ja) 2019-12-25

Family

ID=52829276

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016556777A Expired - Fee Related JP6625061B2 (ja) 2014-03-11 2015-03-11 固形腫瘍癌を検出する方法

Country Status (9)

Country Link
US (1) US10451626B2 (enExample)
EP (2) EP3117216B1 (enExample)
JP (1) JP6625061B2 (enExample)
AU (2) AU2015230017B2 (enExample)
CA (2) CA2940445C (enExample)
DK (1) DK3117216T3 (enExample)
FI (1) FI3117216T3 (enExample)
RU (1) RU2720148C9 (enExample)
WO (1) WO2015137870A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3312749T3 (pl) 2012-03-05 2024-10-07 Oy Arctic Partners Ab Metody i aparaty do prognozowania ryzyka raka gruczołu krokowego i objętości gruczołu krokowego
PE20170298A1 (es) 2014-03-28 2017-04-18 Opko Diagnostics Llc Composiciones y metodos relacionados con el diagnostico del cancer de prostata
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
JP6749337B2 (ja) 2015-03-27 2020-09-02 オプコ・ダイアグノスティクス・リミテッド・ライアビリティ・カンパニーＯｐｋｏ Ｄｉａｇｎｏｓｔｉｃｓ，Ｌｌｃ 前立腺抗原標準およびその使用
US11479878B2 (en) 2016-03-16 2022-10-25 Dana-Farber Cancer Institute, Inc. Methods for genome characterization
ES2688213T3 (es) * 2016-07-15 2018-10-31 Proteomedix Ag Método para detectar proteínas en muestras humanas y usos de dichos métodos
FI3577237T3 (fi) * 2017-02-01 2023-08-29 Phadia Ab Menetelmä eturauhassyövän läsnäolon tai puuttumisen osoittamiseksi henkilöillä, joilla on tiettyjä ominaisuuksia
EP3577215A4 (en) * 2017-02-03 2020-12-30 The Johns Hopkins University USE OF MINI-CANCERS FOR PERSONALIZED ANTI-CANCER DRUG PROTOCOLS
RU2664706C2 (ru) * 2017-06-02 2018-08-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский радиологический центр" Министерства здравоохранения Российской Федерации (ФГБУ "НМИРЦ" Минздрава России) Способ прогнозирования клинического статуса рака предстательной железы
JP7127422B2 (ja) * 2017-08-30 2022-08-30 東ソー株式会社 癌を検出する方法及び検出試薬
WO2020205204A1 (en) * 2019-04-03 2020-10-08 Opko Diagnostics, Llc Methods for the detection of prostate cancer
IT202000029948A1 (it) * 2020-12-04 2022-06-04 Nib Biotec S R L Metodo per la diagnosi di tumore alla prostata in pazienti in differente fascia di età
EP4609409A1 (en) * 2022-10-27 2025-09-03 Myome, Inc. Approach for early detection of disease combining multiple data sources
WO2024092136A2 (en) * 2022-10-28 2024-05-02 Memorial Sloan-Kettering Cancer Center Machine learning modeling for inpatient prediction

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030219840A1 (en) 2002-05-24 2003-11-27 Mikolajczyk Stephen D. Method of analyzing proenzyme forms of prostate specific antigen in serum to improve prostate cancer detection
US20050277137A1 (en) 2003-08-15 2005-12-15 University Of Pittsburgh Diagnostic multimarker serological profiling
KR100830811B1 (ko) * 2006-09-18 2008-05-20 충북대학교 산학협력단 종양표시인자 검출용 바이오센서
FR2934698B1 (fr) 2008-08-01 2011-11-18 Commissariat Energie Atomique Procede de prediction pour le pronostic ou le diagnostic ou la reponse therapeutique d'une maladie et notamment du cancer de la prostate et dispositif permettant la mise en oeuvre du procede.
CA2750062A1 (en) 2009-01-19 2010-07-22 Katrin Stedronsky Diagnostic assays for prostate cancer using psp94 and psa biomarkers
US20120121618A1 (en) 2009-02-12 2012-05-17 Dana-Farber Cancer Institute, Inc. Predicting And Treating Prostate Cancer
EP2407555A1 (en) 2010-07-14 2012-01-18 Fundació Institut de Recerca Hospital Universitari Vall d'Hebron, Fundació Privada Methods and kits for the diagnosis of prostate cancer
US9732389B2 (en) 2010-09-03 2017-08-15 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
US20120202888A1 (en) 2010-10-08 2012-08-09 The Brigham And Women's Hospital, Inc. Biomarkers of prostate cancer and predicting mortality
US20120150032A1 (en) 2010-12-13 2012-06-14 Julius Gudmundsson Sequence Variants Associated with Prostate Specific Antigen Levels
EP2659005A4 (en) 2010-12-28 2016-08-24 Caris Mpi Inc MOLECULAR PROFILING OF CANCER
US9753043B2 (en) * 2011-12-18 2017-09-05 20/20 Genesystems, Inc. Methods and algorithms for aiding in the detection of cancer
US20150094221A1 (en) 2012-05-16 2015-04-02 Phadia Ab Method for Indicating the Presence or Non-Presence of Prostate Cancer
EP3327146A1 (en) 2012-11-20 2018-05-30 Phadia AB Method for indicating a presence or non-presence of aggressive prostate cancer
RU2669809C2 (ru) * 2012-11-20 2018-10-16 Пхадиа Аб Способ прогноза для индивидуумов с раком предстательной железы

Also Published As

Publication number Publication date
AU2021232712A1 (en) 2021-10-14
RU2016139491A (ru) 2018-04-16
WO2015137870A1 (en) 2015-09-17
AU2021232712B2 (en) 2024-10-03
US20170108501A1 (en) 2017-04-20
EP4220170A3 (en) 2023-12-13
AU2015230017B2 (en) 2021-06-17
EP4220170A2 (en) 2023-08-02
JP2017508970A (ja) 2017-03-30
CA2940445A1 (en) 2015-09-17
RU2720148C2 (ru) 2020-04-24
EP3117216B1 (en) 2023-01-11
FI3117216T3 (fi) 2023-04-27
HK1231559A1 (en) 2017-12-22
AU2015230017A1 (en) 2016-09-08
CA2940445C (en) 2021-11-30
EP3117216A1 (en) 2017-01-18
US10451626B2 (en) 2019-10-22
DK3117216T3 (da) 2023-04-03
CA3134289A1 (en) 2015-09-17
RU2720148C9 (ru) 2020-09-28
RU2016139491A3 (enExample) 2018-10-15

Similar Documents

Publication Publication Date Title
JP6625061B2 (ja) 固形腫瘍癌を検出する方法
US10431326B2 (en) Method for indicating a presence or non-presence of aggressive prostate cancer
RU2669809C2 (ru) Способ прогноза для индивидуумов с раком предстательной железы
JP2015524052A (ja) 前立腺癌の存在または不存在の提示方法
JP2022179483A (ja) 特定の特徴を有する個体において前立腺癌の存在または不存在を示すための方法
CN105051206B (zh) 用于指示侵袭性前列腺癌的存在或不存在的方法
HK1231559B (en) Method for detecting a solid tumor cancer
HK1215594B (en) Method for indicating a presence or non-presence of aggressive prostate cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180308

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190529

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191126

R150 Certificate of patent or registration of utility model

Ref document number: 6625061

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees